LLY — ELI LILLY & Co catalysts

11 verified catalyst event(s) for ELI LILLY & Co (ticker LLY). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-08-01 — Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08 (month)
in 1mo
ESTIMATED
READOUT
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type
Phase 3 · Diabetes Mellitus, Type 2
LLY ELI LILLY & Co Retatrutide, Semaglutide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-08 (month)
in 1mo
ESTIMATED
READOUT
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol
Phase 2 · Alcohol Use Disorder
LLY ELI LILLY & Co Mazdutide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-09 (month)
in 2mo
ESTIMATED
READOUT
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Y
Phase 3 · Systemic Juvenile Idiopathic Arthritis
LLY ELI LILLY & Co Baricitinib, Tocilizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-09 (month)
in 2mo
ESTIMATED
READOUT
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity an
Phase 2 · Overweight, Obesity
LLY ELI LILLY & Co Tirzepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-09 (month)
in 2mo
ESTIMATED
READOUT
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (
Phase 3 · Perennial Allergic Rhinitis (PAR)
LLY ELI LILLY & Co LY3650150, Standard therapy for INCS ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-10 (month)
in 3mo
ESTIMATED
READOUT
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes
Phase 3 · Type 2 Diabetes
LLY ELI LILLY & Co Retatrutide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
READOUT
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea
Phase 3 · OSA, Overweight or Obesity
LLY ELI LILLY & Co Orforglipron ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
READOUT
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 D
Phase 3 · Type 1 Diabetes, Obesity
LLY ELI LILLY & Co Tirzepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
READOUT
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and
Phase 3 · Type 1 Diabetes, Obesity
LLY ELI LILLY & Co Tirzepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
READOUT
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated Wit
Phase 2 · Diabetes Mellitus, Type 2
LLY ELI LILLY & Co LY3938577, Degludec ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
READOUT
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
Phase 2 · Acute Pain, Molar
LLY ELI LILLY & Co LY4515100 ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.